Do ditans and gepants have a place in acute migraine treatment?

2022 ◽  
Vol 28 (1) ◽  
pp. 20
Author(s):  
Clarissa Chan
Keyword(s):  
Migraine Treatment ◽  
Acute Migraine ◽  
Acute Migraine Treatment

Targeted Review: Medications for Acute Migraine Treatment

2013 ◽  
Vol 40 (S3) ◽  
pp. S10-S32 ◽  
Author(s):  
Irene Worthington ◽  
Tamara Pringsheim ◽  
Marek J. Gawel ◽  
Jonathan Gladstone ◽  
Paul Cooper ◽  
...  
Keyword(s):  
Migraine Treatment ◽  
Acute Migraine ◽  
Acute Migraine Treatment

scholarly journals Effect of Calcitonin Gene-Related Peptide Receptor Antagonists on Migraine Treatment: A Meta-Analysis

2021 ◽  
Author(s):  
Jiyoung Kim ◽  
Kyoungjune Pak ◽  
Gha-Hyun Lee ◽  
Jae Wook Cho ◽  
Hyun-Woo kim
Keyword(s):  
Meta Analysis ◽  
Calcitonin Gene Related Peptide ◽  
Migraine Treatment ◽  
Acute Migraine ◽  
Cgrp Receptor ◽  
Receptor Antagonists ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Cgrp Receptor Antagonists ◽  
Acute Migraine Treatment

Abstract Background: The pathophysiology of migraine has been researched incessantly, and it has been suggested that calcitonin gene-related peptide (CGRP) is associated with migraine attacks. CGRP receptor blockers are attracting attention for migraine prevention and treatment of acute episodes, and CGRP receptor antagonists have been shown to be effective in treating acute migraine headaches. This meta-analysis aimed to assess the effect of available CGRP receptor antagonists, focusing on their therapeutic doses for acute migraine treatment.Methods: We performed a systematic search of MEDLINE (from inception to March 2021) and EMBASE (from inception to March 2021) for English publications using the keywords “migraine” and “Calcitonin gene-related peptide,” limited to human studies.Results: Five studies that focused on examining the effects of CGRP receptor antagonists on acute migraine treatment met the eligibility criteria for this meta-analysis. The pooled analysis demonstrated that the CGRP receptor antagonist improved freedom from pain (OR=2.066, 95% confidence interval [CI] 1.766–2.418, I2=0%), absence of bothersome symptoms (OR=1.606, 95% CI=1.408–1.830, I2=0%), pain relief (OR=1.791, 95% CI=1.598–2.008, I2=0%), and freedom from nausea (OR=1.361, 95% CI=1.196–1.548, I2=0%), significantly more than the placebo. Conclusions: CGRP receptor antagonists are effective for acute migraine treatment and are expected to be used clinically as emerging therapeutic agents.

Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study

Cephalalgia ◽  
2012 ◽  
Vol 32 (3) ◽  
pp. 226-235 ◽  
Author(s):  
M Lantéri-Minet ◽  
G Mick ◽  
B Allaf
Keyword(s):  
Migraine Treatment ◽  
Acute Migraine ◽  
Acute Migraine Treatment

Validation of the Revised Patient Perception of Migraine Questionnaire: Measuring Satisfaction With Acute Migraine Treatment

2006 ◽  
Vol 46 (2) ◽  
pp. 240-252 ◽  
Author(s):  
Dennis A. Revicki ◽  
Miriam Kimel ◽  
Kathy Beusterien ◽  
Jackie W. Kwong ◽  
Julie A. Varner ◽  
...  
Keyword(s):  
Patient Perception ◽  
Migraine Treatment ◽  
Acute Migraine ◽  
Acute Migraine Treatment

scholarly journals Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient

2013 ◽  
Vol 40 (S3) ◽  
pp. S33-S62 ◽  
Author(s):  
Irene Worthington ◽  
Tamara Pringsheim ◽  
Marek J. Gawel ◽  
Jonathan Gladstone ◽  
Paul Cooper ◽  
...  
Keyword(s):  
Literature Review ◽  
Treatment Strategies ◽  
Drug Efficacy ◽  
Migraine Treatment ◽  
Acute Migraine ◽  
Review Section ◽  
Specific Patient ◽  
Medical Disorders ◽  
Acute Medication ◽  
Acute Migraine Treatment

ABSTRACT:Background:In our targeted review (Section 2), 12 acute medications received a strong recommendation for use in acute migraine therapy while four received a weak recommendation for use. Strong recommendations were made to avoid use of two other medications, except for exceptional circumstances. Two anti-emetics received strong recommendations for use as needed.Objective:To organize the available acute migraine medications into acute migraine treatment strategies in order to assist the practitioner in choosing a specific medication(s) for an individual patient.Methods:Acute migraine treatment strategies were developed based on the targeted literature review used for the development of this guideline (Section 2), and a general literature review. Expert consensus groups were used to refine and validate these strategies.Results:Based on evidence for drug efficacy, drug side effects, migraine severity, and coexistent medical disorders, our analysis resulted in the formulation of eight general acute migraine treatment strategies. These could be grouped into four categories: 1) two mild-moderate attack strategies, 2) two moderate-severe attack or NSAID failure strategies, 3) three refractory migraine strategies, and 4) a vasoconstrictor unresponsive-contraindicated strategy. In addition, strategies were developed for menstrual migraine, migraine during pregnancy, and migraine during lactation. The eight general treatment strategies were coordinated with a “combined acute medication approach” to therapy which used features of both the “stratified” and the “step care across attacks” approaches to acute migraine management.Conclusions:The available medications for acute migraine treatment can be organized into a series of strategies based on patient clinical features. These strategies may help practitioners make appropriate acute medication choices for patients with migraine.

Sign in / Sign up

Export Citation Format

Share Document